NCT01734928: Phase 3 - Safety/Efficacy of Pom Bortezomib and Low-dose Dex in relapsed MM (OPTIMISMM)
The OPTIMISMM trial The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose...
Dec 6, 2012
389
NCT01712789: Phase 3 - Pomalidomide + Dex (Low Dose) Refractory or Relapsed Multiple Myeloma STRATUS
STRATUS RRMM Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed...
Dec 6, 2012
113
NCT01311687: Phase 3 - Efficacy & Safety of Pomalidomide & Low dose dex Vs High-Dose Dex - NIMBUS
MM-003 The NIMBUS trial The purpose of this study is to compare efficacy and safety of pomalidomide in combination with low-dose...
Dec 9, 2011
326
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
MMRF CoMMpass Study Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) The primary...
Dec 9, 2011
848
NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)
ELOQUENT - 2 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple...
Dec 18, 2010
102
NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE
THE ASPIRE TRIAL Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in...
Dec 10, 2010
545
NCT01023308: Phase 3 - Panobinostat or Placebo With Bortezomib & Dex in Relapsed Myeloma PANORAMA-1
PANORAMA Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome...
Dec 12, 2009
246
NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
Phase III trial SWOG S0777 SWOG0777 0777 Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously...
Dec 30, 2008
402
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
FIRST study IFM 07-01 CC-5013-MM020 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan,...
Dec 14, 2008
442
NCT00430365: Phase 3 - IFM2005-02 - Maintenance Therapy Using Lenalidomide in Myeloma
IFM2005-02 Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02) NCT00430365: Phase 3 - Maintenance Therapy Using Lenalidomide...
Dec 26, 2007
366
NCT00424047: Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma
Multiple Myeloma (010) MM-010 NCT00424047: A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated...
Dec 14, 2007
204
NCT00574288: Phase 1/2: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - GEN501 study
GEN501 study Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma Establishment of safety profile of HuMax-CD38 when given as...
Dec 12, 2007
430
NCT00405756: Phase 3 - A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects
MM-015 study NCT00405756 A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. The purpose...
Dec 7, 2006
100
NCT00056160 : Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma
Multiple Myeloma (009) MM-009 NCT00056160 : Phase 3 - CC-5013 Plus Dex Versus Dex Alone in Previously Treated Subjects With Multiple...
Dec 11, 2003
150